Corvus Pharmaceuticals, Inc. 8-K

What Happened

• Corvus Pharmaceuticals, Inc. (CRVS) filed a Form 8‑K on March 12, 2026 (Item 2.02) to announce its financial results for the fourth quarter and full year ended December 31, 2025, and to provide a business update.
• The company furnished a press release dated March 12, 2026 as Exhibit 99.1 to the filing. The filing was signed by Leiv Lea, Chief Financial Officer.

Key Details

• Filing date: March 12, 2026. Reporting period covered: quarter and year ended December 31, 2025.
• Item reported: 2.02 (Results of Operations and Financial Condition); Exhibit 99.1 = press release.
• The press release contains the reported quarterly results, full‑year results and a business update (investors should read Exhibit 99.1 for specific revenue, net income/loss, cash position and guidance details).
• The Form 8‑K did not announce executive changes, mergers, or bankruptcy filings.

Why It Matters

• This filing signals Corvus disclosed its latest earnings and balance‑sheet position; those figures (revenue, earnings/loss, cash runway) can affect stock performance and near‑term financing or development plans.
• Retail investors should review the attached press release for the concrete financial metrics and any commentary on pipeline progress, guidance, or capital resources to assess the company’s financial health and operational outlook.
• Because the 8‑K only furnishes the press release, investors should look for a subsequent 10‑K/10‑Q or investor presentation for additional detail and audited financial statements.